- COVID-19 disruptions affecting business, preclinical studies, and clinical trials.
- High incidence of delay or failure in biopharmaceutical product development.
- Uncertainty and potential negative impacts from Brexit.
Amryt Pharma plc
Greenhouse gas emissions & sustainability report data
Figures are as stated in the company's own report and may use different boundaries, units or methods (for example market-based vs location-based Scope 2), so compare with care.
📈 Emissions by Report Period
| Report period | Headline emissions figure reported |
|---|---|
| 2020 | 441.38 tCO2e/year |
Each row is the headline figure extracted from a different report; scope coverage and methodology can change between years.